脑淀粉样血管病的分子影像研究进展  

Advances in molecular imaging of cerebral amyloid angiopathy

作　　者：沙宇惠 倪俊 Sha Yuhui;Ni Jun(Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,State Key laboratory of Complex Severe and Rare Diseases,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院神经科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院神经科疑难重症及罕见病国家重点实验室,北京100730

出　　处：《中华神经科杂志》2023年第8期932-938,共7页Chinese Journal of Neurology

基　　金：中国医学科学院医学与健康科技创新工程项目(2021-I2MC&T-B-004)。

摘　　要：脑淀粉样血管病(CAA)是以β-淀粉样蛋白(Aβ)沉积于脑血管壁中层及外膜为主要病理特征的一类年龄相关脑小血管病。多种分子影像技术如淀粉样蛋白正电子发射体层摄影(PET)、18F-氟脱氧葡萄糖-PET等已逐渐应用于CAA患者。其中,淀粉样蛋白PET显像通过正电子核素标记的显像剂特异性结合病理标志物,反映Aβ沉积的分布和负荷,可为诊断CAA提供定性与定量信息,然其在鉴别CAA与其他Aβ相关疾病如阿尔茨海默病方面价值有限。其他分子影像如tau-PET、单光子发射计算机体层摄影等及新型高选择性示踪剂也在被广泛研究中。文中主要就CAA分子影像进展进行综述。Cerebral amyloid angiopathy(CAA)is a common age-related small vessel disease characterized by amyloid-β(Aβ)deposition in the wall of small arterioles and capillaries of the leptomeninges and cerebral cortex.Several molecular imaging technologies such as amyloid-βpositron-emission tomography(PET)and ^(18)F-fluorodeoxyglucose-PET have been successfully applied in the patients with CAA.Amyloid-PET may indicate the distribution and burden of Aβ deposition by the tracer′s specific binding to the pathological markers,providing qualitative and quantitative information for the diagnosis of CAA.However,amyloid-β PET is inadequate to differentiate CAA from other Aβ-related diseases like Alzheimer′s disease.Other novel techniques of molecular imaging including tau-PET,single photon emission computed tomography and other highly selective PET radioligands have been investigated widely at present.This article mainly reviewed the advances in molecular imaging of CAA.

关 键 词：脑淀粉样血管病 正电子发射断层显像术 脑出血 分子影像 Β淀粉样蛋白 

分 类 号：R743[医药卫生—神经病学与精神病学]